Voyager Therapeutics (VYGR) Stock Rating Reaffirmed by Zacks Investment Research

Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “sell” rating reissued by Zacks Investment Research in a report released on Saturday.

According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

A number of other analysts have also recently weighed in on VYGR. BidaskClub raised shares of Voyager Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 26th. Morgan Stanley assumed coverage on shares of Voyager Therapeutics in a research report on Friday, February 2nd. They issued an “overweight” rating on the stock. Canaccord Genuity restated a “buy” rating and issued a $26.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, January 23rd. Chardan Capital restated a “hold” rating and issued a $17.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, October 31st. Finally, Wedbush restated a “positive” rating and issued a $31.00 price target (down from $36.00) on shares of Voyager Therapeutics in a research report on Tuesday, October 31st. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and thirteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $26.90.

Voyager Therapeutics (NASDAQ:VYGR) traded up $0.17 during midday trading on Friday, reaching $18.18. 215,916 shares of the company were exchanged, compared to its average volume of 296,692. The company has a market capitalization of $566.41, a PE ratio of -6.40 and a beta of 4.04. Voyager Therapeutics has a twelve month low of $8.10 and a twelve month high of $25.99.

In other Voyager Therapeutics news, insider Bernard Ravina sold 3,630 shares of the business’s stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $16.40, for a total value of $59,532.00. Following the transaction, the insider now directly owns 7,353 shares in the company, valued at $120,589.20. The transaction was disclosed in a document filed with the SEC, which is available through this link. 8.00% of the stock is owned by insiders.

Hedge funds have recently made changes to their positions in the company. Thompson Davis & CO. Inc. lifted its position in shares of Voyager Therapeutics by 67.7% during the fourth quarter. Thompson Davis & CO. Inc. now owns 7,485 shares of the company’s stock worth $124,000 after purchasing an additional 3,021 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Voyager Therapeutics during the third quarter worth approximately $270,000. Bailard Inc. acquired a new position in shares of Voyager Therapeutics during the fourth quarter worth approximately $232,000. Rhumbline Advisers lifted its position in shares of Voyager Therapeutics by 34.7% during the second quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock worth $144,000 after purchasing an additional 4,144 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Voyager Therapeutics by 8.9% during the second quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock worth $153,000 after purchasing an additional 1,399 shares in the last quarter. Institutional investors own 36.18% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Voyager Therapeutics (VYGR) Stock Rating Reaffirmed by Zacks Investment Research” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/10/voyager-therapeutics-vygr-stock-rating-reaffirmed-by-zacks-investment-research.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply